Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma

Despite recent advances in the treatment of multiple myeloma, patients with this disease still inevitably relapse and become refractory to existing therapies. Mutations in K-RAS, N-RAS and B-RAF are common in multiple myeloma, affecting 50% of patients at diagnosis and >70% at relapse. However, t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Haematologica
Main Authors: Ramakrishnan, Vijay G., Miller, Kevin C., Macon, Elaine P., Kimlinger, Teresa K., Haug, Jessica, Kumar, Sanjay, Gonsalves, Wilson I., Rajkumar, S. Vincent, Kumar, Shaji K.
Formato: Artigo
Idioma:Inglês
Publicado em: Ferrata Storti Foundation 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6886422/
https://ncbi.nlm.nih.gov/pubmed/30846494
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2018.211110
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados